T2 Biosystems (NASDAQ:TTOO) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research note issued to investors on Monday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, Canaccord Genuity Group lifted their price target on shares of T2 Biosystems from $3.00 to $5.00 and gave the stock a “hold” rating in a research note on Tuesday, July 30th.

T2 Biosystems Stock Down 3.9 %

Shares of TTOO stock opened at $0.49 on Monday. T2 Biosystems has a 1 year low of $0.42 and a 1 year high of $8.38. The firm’s fifty day simple moving average is $1.27 and its 200 day simple moving average is $3.37.

Institutional Investors Weigh In On T2 Biosystems

An institutional investor recently raised its position in T2 Biosystems stock. Virtu Financial LLC boosted its holdings in shares of T2 Biosystems, Inc. (NASDAQ:TTOO) by 29.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,096 shares of the medical equipment provider’s stock after buying an additional 3,018 shares during the period. Virtu Financial LLC owned about 0.24% of T2 Biosystems worth $39,000 as of its most recent SEC filing. 23.18% of the stock is owned by institutional investors.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.